Fate Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fate Therapeutics, Inc.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals.
Investment from Janssen helps to validate the platform developed by the San Diego-based company.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Tfinity Therapeutics, Inc.